Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2026-12-24
Target enrollment:
Participant gender:
Summary
To verify the role of nab-paclitaxel in neoadjuvant therapy for esophageal squamous cell
carcinoma, the investigators designed a prospective, randomized, controlled , multicente
phase II trial, to investigate the efficacy and safety of nab-paclitaxel combined with
cisplatin as neoadjuvant therapy followed by surgery versus surgery alone for esophageal
squamous cell carcinoma.